Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

MorphoSys AG : to Present at Three Investor Conferences in November

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/14/2011 | 03:05pm CET

MorphoSys AG / MorphoSys to Present at Three Investor Conferences in November . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that management will present at three international investor conferences in November.

9th WestLB Deutschland Conference
Date:                          November 16, 2011 at 10:15am CET (09:15am GMT; 
                                  04:15am EST)
Venue:                        Frankfurt, Germany
Participants:                Jens Holstein, CFO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate
                                  Communications & IR

Deutsches Eigenkapitalforum
Date:                          November 22, 2011 at 09:45am CET (08:45am GMT;
                                  03:45am EST)
Venue:                        Frankfurt, Germany
Participants:                Dr. Simon Moroney, CEO of MorphoSys AG
                                  Jens Holstein, CFO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate
                                  Communications & IR

23rd Annual Piper Jaffray Healthcare Conference
Date:                          November 30, 2011 at 01:30pm EST (06:30pm GMT;
                                  07:30pm CET)
Venue:                        New York, USA
Participants:                Dr. Simon Moroney, CEO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate 
                                  Communications & IR

A PDF version of the Company presentation will be provided at www.morphosys.com/presentations:
http://www.morphosys.com/presentations. Links to the webcast, if available, are filed under www.morphosys.com/conference-calls:
http://www.morphosys.com/conference-calls.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The Company's AbD Serotec unit uses HuCAL and other technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Through its own development efforts and successful partnerships in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline:
http://www.morphosys.com/pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com:
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, arYla®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

[email protected]:
mailto:[email protected]

Conference Announcement November:
http://hugin.info/130295/R/1563518/484733.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

HUG#1563518

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
02/20GALAPAGOS : MorphoSys and Galapagos Present Results from a Phase 1 Study with MO..
AQ
02/20MORPHOSYS AG : MorphoSys Announces That Tremfya(R) (Guselkumab) Data Demonstrate..
AC
02/20MORPHOSYS : Announces That Tremfya(R) (Guselkumab) Data Demonstrated Long-Term S..
PU
02/20MORPHOSYS : Announces That Tremfya(R) (Guselkumab) Data Demonstrated Long-Term S..
EQ
02/17MORPHOSYS : and Galapagos Present Results from a Phase 1 Study with MOR106 in At..
PU
02/17MORPHOSYS : and Galapagos Present Results from a Phase 1 Study with MOR106 in At..
EQ
02/08MORPHOSYS : Patent Application Titled "Method for the Treatment of Multiple Myel..
AQ
2017MORPHOSYS AG : Release according to Article 26a of the WpHG [the German Securiti..
EQ
2017MORPHOSYS : to Present at Upcoming Investor Conferences
AQ
2017MORPHOSYS : to Present at Upcoming Investor Conferences
PU
More news
News from SeekingAlpha
02/16Morphosys (MPSYY) Presents At Leerink Partners 7th Annual Global Healthcare C.. 
01/10Morphosys (MPSYY) Presents At 36th Annual J.P. Morgan Healthcare Conference -.. 
2017MORPHOSYS : Partnered Drug Development Growth Is Its Key Value Driver 
2017Morphosys (MPSYY) Conference Call (L-MIND Data) - Slideshow 
2017WEEK IN REVIEW : Walgreens Boots Alliance Spends $420 Million For China Pharmacy.. 
Financials (€)
Sales 2017 62,0 M
EBIT 2017 -62,1 M
Net income 2017 -65,7 M
Finance 2017 259 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 31,7x
EV / Sales 2018 41,9x
Capitalization 2 224 M
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 81,8 €
Spread / Average Target 8,1%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Günter Wellnhofer Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-5.92%2 749
CELLTRION, INC.--.--%36 184
IQVIA HOLDINGS INC6.93%21 157
LONZA GROUP-7.82%18 346
INCYTE CORPORATION-6.91%18 156
NEKTAR THERAPEUTICS40.66%13 138